Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

Expert Opinion on Biological Therapy

Volumn 4, Issue 7, 2004, Pages 1129-1138

  Baldridge, Jory R ^a   McGowan, Patrick ^a   Evans, Jay T ^a   Cluff, Christopher ^a   Mossman, Sally ^a   Johnson, David ^a   Persing, David ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; AGP; Immunomodulators; Innate immunity; Lipid A mimetics; MPL; TLR4; Toll like receptor; Vaccine

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; GLUCOSAMINE DERIVATIVE; GLUCOSAMINIDE 4 PHOSPHATE DERIVATIVE; HEPATITIS B VACCINE; HERPES VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 12; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MALARIA VACCINE; MELANOMA VACCINE; MITOGEN ACTIVATED PROTEIN KINASE; MPL; PHOSPHORYL LIPID A; POLLINEX; RC 526; RC 527; RIBI 529; STREPTOCOCCUS VACCINE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS B; HERPES; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MALARIA; MELANOMA; NONHUMAN; POLLEN ALLERGY; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AGED; ANIMALS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CHILD; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; GLYCOLIPIDS; HUMANS; IMMUNOLOGIC FACTORS; LIPID A; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PROTOZOAN INFECTIONS; RECEPTORS, CELL SURFACE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; VIRAL VACCINES; VIRUS DISEASES; VIRUS REPLICATION;

CORIXA; SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR MINNESOTA; STREPTOCOCCUS;

EID: 3142690381     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.7.1129     Document Type: Review

References (56)

1. TAKEDA K, AKIRA S: TLR signaling pathways. Semin. Immunol. (2004) 16(1):3-9.
2. ZHANG D, ZHANG G, HAYDEN MS et al.: A toll-like receptor that prevents infection by uropathogenic bacteria. Science (2004) 303(5663):1522-1526.
3. POLTORAK A, HE X, SMIRNOVA I et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282(5396):2085-2088. The first identification of a microbial product (LPS) as a TLR agonist.
4. POLTORAK A, RICCIARDI-CASTAGNOLI P, CITTERIO S, BEUTLER B: Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc. Natl. Acad. Sci. USA (2000) 97(5):2163-2167.
5. ULEVITCH RJ: Endotoxin opens the Tollgates to innate immunity. Nat. Med. (1999) 5(2):144-145. The role of LPS in the induction of innate immunity.
6. RIBI ES, MIZUNO Y, NOWOTNY A et al.: Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol. Immunother. (1979) 7:43-58.
7. MYERS K, TRUCHOT AT, WARD J, HUDSON Y, ULRICH JT: A critical determinant of lipid A endotoxic activity. In: Cellular and Molecular Aspects of Endotoxin Reactions. Nowotny A, Spitzet JJ, Zieglet EJ (Eds), Amsterdam, The Netherlands (1990):145-156.
8. ULRICH JT, MYERS KR: Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. (1995) 6:495-524. An excellent, in-depth review of MPL adjuvant therapy.
9. EVANS JT, CLUFF CW, JOHNSON DA et al.: Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines (2003) 2(2):219-229.
10. VIGLIANTI GA, LAU CM, HANLEY TM et al.: Activation of autoreactive B cells by CpG dsDNA. Immunity (2003) 19(6):837-847.
11. SACHER T, KNOLLE P, NICHTERLEIN T et al.: CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur. J. Immunol. (2002) 32(12):3628-3637.
12. JOHNSON DA, SOWELL CG, JOHNSON CL et al.: Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. (1999) 9(15):2273-2278. Details the synthesis and biological activity of a novel class of synthetic TLR4 agonists.
13. ULRICH JM, LANGE W: Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A. Adv. Biosci. (1988) 68:167-178.
14. MADONNA GL, FUNCKES DC, RIBI EE: Monophosphoryl lipid A and trehalose dimycolate therapy enhances survival in sublethally irradiated mice challenged with Klebsiella pneumoniae. Adv. Biosci. (1988) 68:351-356.
15. PERSING DH, COLER RN, LACY MJ et al.: Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. (2002) 10(10 Suppl.):S32-S37.
16. BALDRIDGE JR, CLUFF CW, EVANS JT et al.: Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin Res. (2002) 8(6):453-458.
17. AYABE T, SATCHELL DP, WILSON CL et al.: Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. (2000) 1(2):113-118.
18. TOSHCHAKOV V, JONES BW, PERERA PY et al.: TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. (2002) 3(4):392-398.
19. KAWAI T, ADACHI O, OGAWA T, TAKEDA K, AKIRA S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11(1):115-122.
20. AKIRA S: Mammalian Toll-like receptors. Curr. Opin. Immunol. (2003) 15(1):5-11. A good review of TLRs.
21. KAISHO T, AKIRA S: Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta (2002) 1589(1):1-13.
22. AGRAWAL S, AGRAWAL A, DOUGHTY B et al.: Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J. Immunol. (2003) 171(10):4984-4989.
23. PULENDRAN B, KUMAR P, CUTLER CW, MOHAMADZADEH M, VAN DYKE T, BANCHEREAU J: Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. (2001) 167(9):5067-5076.
24. JOTWANI R, PULENDRAN B, AGRAWAL S, CUTLER CW: Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur. J. Immunol. (2003) 33(11):2980-2986.
25. HIRSCHFELD M, WEIS JJ, TOSHCHAKOV V et al.: Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. (2001) 69(3):1477-1482.
26. RE F, STROMINGER JL: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. (2001) 276(40):37692-37699.
27. REDECKE V, HACKER H, DATTA SK et al.: Cutting edge: activation of toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. (2004) 172(5):2739-2743.
28. ITO T, AMAKAWA R, KAISHO T et al.: Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. (2002) 195(11):1507-1512.
29. DE BECKER G, MOULIN V, PAJAK B et al.: The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. (2000) 12(6):807-815.
30. BALDRIDGE JR, YORGENSEN Y, WARD JR, ULRICH JT: Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine (2000) 18(22):2416-2425.
31. CLAEYS S, DE BELDER T, HOLTAPPELS G et al.: Human beta-defensins and toll-like receptors in the upper airway. Allergy (2003) 58(8):748-753.
32. THOELEN S, VAN DAMME P, MATHEI C et al.: Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine (1998) 16(7):708-714.
33. THOELEN S, DE CLERCQ N, TORNIEPORTH N: A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine (2001) 19(17-19):2400-2403.
34. STANBERRY LR, SPRUANCE SL, CUNNINGHAM AL et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. (2002) 347(21):1652-1661.
35. COREY L, LANGENBERG AG, ASHLEY R et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 282(4):331-340.
36. VERNACCHIO L, BERNSTEIN H, PELTON S et al.: Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine (2002) 20(31-32):3658-3667.
37. nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) Abstract G-144.
38. STOVER AG, DA SILVA CORREIA J, EVANS JT et al.: Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J. Biol. Chem. (2004) 279(6):4440-4449. Studies on the structure/function analysis of synthetic TLR4 agonists
39. LUSTER AD: The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. (2002) 14(1):129-135.
40. BELARDELLI F, FERRANTINI M: Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. (2002) 23(4):201-208.
41. ISMAILI J, RENNESSON J, AKSOY E et al.: Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol. (2002) 168(2):926-932.
42. BERGER FM: The effect of endotoxin on resistance to infection and disease. Adv. Pharmacol. (1967) 5:19-46.
43. NETER E: Endotoxins and the immune response. Curr. Top. Microbiol. Immunol. (1969) 47:82-124.
44. RICHWALD GA: Imiquimod. Drugs Today (Barc.) (1999) 35(7):497-511.
45. COLLINS PL, CHANOCK RM, MURPHY BR: Respiratory syncytial virus. In: Fields Virology. Knipe DM, Howley PM (Eds) Lippincott, Williams and Wilkins, Philadelphia, USA (2001):21443-21486.
46. CULLEY FJ, POLLOTT J, OPENSHAW PJ: Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J. Exp. Med. (2002) 196(10):1381-1386.
47. ROHDE G, WIETHEGE A, BORG I et al.: Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax (2003) 58(1):37-42.
48. DRACHENBERG KJ, WHEELER AW, STUEBNER P, HORAK F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy (2001) 56(6):498-505.
49. MOTHES N, HEINZKILL M, DRACHENBERG KJ et al.: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy (2003) 33(9):1198-1208.
50. MALAKOFF D: Public health. Aluminum is put on trial as a vaccine booster. Science (2000) 288(5470):1323-1324.
51. MBAWUIKE IN, ACUNA C, CABALLERO D et al.: Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma a production by monophosphoryl lipid. A. Cell. Immunol. (1996) 173(1):64-78.
52. DESOMBERE I, VAN DER WIELEN M, VAN DAMME P et al.: Immune response of HLA DQ2 positive subjects vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine (2002) 20(19-20):2597-2602.
53. JACQUES P, MOENS G, DES OMBERE I et al.: The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine (2002) 20(31-32):3644-3649.
54. STOUTE JA, SLAOUI M, HEPPNER DG et al.: A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. (1997) 336(2):86-91.
55. SOSMAN JA, UNGER JM, LI U PY et al.: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. (2002) 20(8):2067-2075.
56. RUDBACH JM, MYERS KR, RECHTMAN DJ, ULRICH JT: Prophylactic use of monophosphoryl lipid A in patients at risk for sepsis. In: Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies. Levin J, van Deventer SJH, van der Poll T, Sturk A (Eds), Wiley-Liss, Inc., New York, USA (1994):107-124.